stackBETA

Daily

  • Log

Verify

  • Cabinet · stacks
  • Vials · inventory

Build

  • Reconstitution

Plan

  • Can I get it?
  • Compare
  • Synergy check

Learn

  • Encyclopedia
  • Common stacks
  • Pulse
  • Methodology

Info

  • Partners & programs

Stack · v0.1 beta

stackBETAv0.1
LogEncyclopediaPulse
MethodologyPartners & programs
← Back to your stack
Monograph
RESEARCH GREYP-074
Recovery

Bronchogen

Tetrapeptide (Ala-Glu-Asp-Leu) from the Khavinson cytomedin lineage. Targeted at lung epithelium — Russian Academy work claims restoration of bronchial epithelial function in chronic-pulmonary-disease + aging cohorts.

ExperimentalRecovery
Typical dose5-10 mg subcutaneous (Khavinson protocol)
Frequencydaily × 10 days, 1-2× yearly
Half-life3h
Citations indexed8
100%50%0%03h6h9h12h15ht½ 3hPK · plasma

How it clearsHalf cleared in ~3h. Most (~96%) gone by ~15h.

DeliveryInjectable
Half-life~3h
EvidenceExperimental
Citations8
Similar compounds
Stack Pro · compare side-by-side

Compare these compounds

Mechanism, evidence, legal path, cost — all side-by-side.

→
Synergy checkCompareReconstitution calc
Research grey

This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.

Mechanism

Same Khavinson framework as Epitalon (pineal), Pinealon (brain), Vesugen (vascular), etc. — each tetrapeptide is targeted at a specific tissue based on Khavinson's gene-regulation hypothesis. Bronchogen is reported to improve respiratory function indices in COPD + post-pneumonia cohorts in Russian gerontology + pulmonology publications. Western RCT replication is absent.

Specifics
Low energy / fatigueCellular aging concerns
Caveats

All efficacy evidence is Khavinson-lineage. Counterfeit + identity-verification problem for grey-market imports from Eastern Europe is severe. NOT a substitute for documented COPD pharmacotherapy.

Evidence levelExperimental
Regulatory statusRussian regulatory pathway only · grey-market import for US/EU · no Western RCT body
DNA / pharmacogenomicsLow — No actionable PG.
Your data · empty

Upload your data to see how it relates to Bronchogen.

Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.

Upload in /history→
Claims & evidence

Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.

  • DMechanistic / anecdotal

    Bronchogen — primary mechanism: tetrapeptide (ala-glu-asp-leu) from the khavinson cytomedin lineage. targeted at lung epithelium — russian academy work claims restoration of bronchial epithelial function in chronic-pulmonary-disease + aging cohorts.

    1 supporting referencesVerified 13d ago
References

External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.

  • ReviewEN
    REVIEWAcademic-fundedVerified 13d ago
    PubMed — Khavinson Bronchogen lung peptide bioregulator
RESEARCH GREYP-074

Russian regulatory pathway only · grey-market import for US/EU · no Western RCT body

Can I get it? →
Reconstitution calculatorBronchogen

Pre-filled with this compound's published dose range: 5-10 mg subcutaneous (Khavinson protocol) · daily × 10 days, 1-2× yearly

Concentration2.50 mg/mL
Draw volume3.000 mL
Insulin syringe300.0 u
Doses per vial0
U-100 syringe — fill to indicatorU-100 · 1 mL
0u25u50u75u100u
Watch

Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.

Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.

No field reports yet

Field reports are added as users share their real-world protocols.

Bronchogen5-10 mg subcutaneous (Khavinson protocol) · daily × 10 days, 1-2× yearly

Next visit & citations

Handoff & sources

Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.

Open Dr PassportMethodologyResearch tableClinician primer
Discussion guide, not prescription

stack is an exploration engine. Output is a discussion guide for a conversation with a licensed provider — never a prescription, dose recommendation, or sourcing instruction. Peptides discussed include compounds with limited human evidence and varying legal status by jurisdiction. Verify everything with a qualified clinician before any decision.

Full terms →
stackv0.1
AudiencesPartners & programsWho Stack is forFor creatorsFor researchersFor pharmaciesFor cliniciansFor press
Trust & regulatoryCalibrationMethodologyFDA statusPharmacy registryPCAC commentMX · COFEPRIS
Built honest. Bilingual from day one.
TodayLibrary
ToolsMe